EMA transparency window 'ajar, not open', say campaigners
This article was originally published in SRA
Executive Summary
The European Medicines Agency may have furthered its efforts towards greater openness by publishing the minutes of three of its main scientific committees, but some critics say that the "transparency window" is not yet fully open, partly because of last year's legal challenges to the agency's policy of providing access to documents.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.